In Brief: Gliatech Adcon-L
This article was originally published in The Gray Sheet
Gliatech Adcon-L: Resorbable barrier gel's premarket approval application will receive expedited review by FDA, the firm says. The PMA was accepted for filing in February. Adcon-L is intended to act as "a barrier to post surgical peridural fibrosis and adhesions following lumbar surgery" ("The Gray Sheet" Aug. 26, 1996, In Brief)...
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.